

## **New Bio-Facilities Planned**

**Novo Nordisk** started construction of a USD \$1.8 BIL, 833,000 sq. ft., new plant at its facilities in Clayton, North Carolina, USA, for manufacture of insulin products. *Source: FiercePharma, April 21, 2016*

**Biogen** plans a new biomanufacturing facility in Luterbach, Solothurn, Switzerland, with 144,000 L capacity, 8 x 18,000 L bioreactors, being added (stainless steel from ABEC), with an output of 10 metric tons (10 MIL grams; 10,000 kg) annually. *Source: BioPharma-Reporter.com, March 25, 2016*

**Shire** is investing \$400 MIL in a new multi-product biomanufacturing facility in County Meath, Ireland, with the facility coming online in 2019. *Source: RTE News, April 15, 2016*

**Sanofi (Genzyme)** is investing USD \$340 MIL to expand its facility in Geel, Belgium, the sole manufacturing site for Myozyme (alglucosidase alfa), adding 8,000 m<sup>2</sup> of manufacturing space to bring in production of other biologics. *Source: LabtechEU, April 29, 2016*

**Intas Biopharmaceuticals Ltd. (India)** is planning a 5,000 L monoclonal antibody manufacturing facility in Sanand, near Ahmedabad, India. *Source: Business Standard, March 31, 2016*

**Purolite**, a chromatography resins supplier, is building a 100,000 sq. ft. fermentation facility in Lantrisant, Wales, UK, for dedicated manufacture of Protein A for its Praesto Protein A resin products. Purolite will have 30% of world Protein A agarose manufacturing capacity. *Source: BioPortfolio, March 18, 2016*

**Novo Nordisk** is investing USD \$110 MIL to build a new bioprocessing facility in Chartres, France, adding 250 staff at this site. *Source: FiercePharma, April 21, 2016*

**Merck KGaA (MerckMillipore)** is expanding a former Sigma-Aldrich facility in Carlsbad, California, USA, to increase its viral and gene therapy production capacity. *Source: Biopharma-Reporter.com, May 6, 2016*

**Pfizer** is investing USD \$21 MIL to expand biosimilar peg-filgrastim (biosimilar version of Amgen's Neulasta) manufacturing capacity in Thebarton, Australia, a bioprocessing facility it obtained through its acquisition of Hospira. *Source: Pharmacy Daily, Sept. 1, 2016*

**Virbac (Bridgeton, Missouri, USA)**, a veterinary vaccines manufacturer, is building a USD \$38 MIL expansion and 144 new jobs. *Source: FierceAnimalHealth, March 30, 2016*

**Vetter Pharma Fertigung GmbH** construction of a USD \$79 MIL, 89,000 sq. ft. additional building in Ravensburg, Germany, for assembly and filling of aseptic prefilled syringes. *Source: Pharmaceutical Outsourcing, March 23, 2016*

### **New Facilities Completed**

**Alvogen** opened its USD \$250 MIL, 127,000 sq. ft. biosimilars manufacturing and CMO facility in Vatnsmyri, Iceland. The facility has 12 x 1,000 L single-use bioreactors, plus downstream and fill-finish facilities. *Source: FiercePharma, May 2, 2016*

**Avid Bioservices (Tustin, California, USA)**, the CMO subsidiary of Peregrine Pharmaceuticals, opened a new bioprocessing facility with 2,000 L single-use bioreactors, expected to support USD \$35-\$40 MIL expansion in CMO revenue/year. *Source: Street Insider, June 2, 2016*

**Johnson & Johnson** opened a new biotech/life science “hub” at Texas Medical Center (Houston, Texas, USA), with this part of the company’s support of early-stage incubator programs. *Source: FierceBiotech, March 2, 2016*

**Merck KGaA (MerckMillipore)** opened a new membrane separation product manufacturing and R&D facility in Carrigtwohill, County Cork, Ireland, a USD \$62 MIL investment with 70 staff. *Source: Irish Examiner, April 20, 2016*

**Merck KGaA (MerckMillipore)** added another 2,000 L Mobius single-use bioreactor at its Biodevelopment Center (CMO facility) in Martillac, France. *Source: Pharmaceutical Outsourcing, May 2, 2016*

**Hamni Science (S. Korea)** is building a 200,000 sq. meter drug and biopharma manufacturing facility in Yantai, Shandong province, China (PRC). *Source: FiercePharma, July 14 and Apr 14, 2016*

**Shire Pharmaceuticals** leased from Cubist Pharmaceuticals over 177,000 sq. ft. of space in Lexington, MA. Shire now has over 1 MIL sq. ft. in the Boston area, rivaling that of other leading local biotech/pharma co.'s. *Source: Boston Business J., March 11, 2016*

**EMD Serono (MerckMillipore, Merck KGaA)** is investing USD \$12 MIL to add 30,000 sq. ft. to its biopharma R&D facility in Bellerica, Massachusetts, USA. *Source: PRNewswire, May 2, 2016*

### **BioINNOVATIONS**

**GE** licensed and will incorporate automation from Zenith Technologies in its KUBio modular facilities biomanufacturing facilities product lines. *Source: PR, Zenith Tech., April 5, 2016*

**Juno Therapeutics (Seattle, Washington, USA)** and **WuXi AppTec (China)** formed a collaboration, JW Biotechnology, adding Juno's CAR-T cellular therapies platform to WuXi services. *Source: BioPharma Dive, April 11, 2016*

### **Wrap-up BioNEWS**

**Amgen** formed a "strategic partnership" with Patheon, a large CMO, with both companies touting the flexibility of their agreement, including working on multiple products. *Source: Outsourcing-Pharma.com, March 15, 2016*

**Brammer Bio** is the new name for the merger of 2 CMOs, Brammer Biopharmaceuticals and Florida Biologix (Alachua, Florida, USA), with strengths including cell and gene therapies. *Source: PRNewswire, March 31, 2016*

**Thermo Fisher** acquired Affymetrix, a life science ‘tools’ and antibodies company, from Origin Technologies Corp. for USD \$1.3 BIL.

*Source: BioPharma-Reporter.com, April 1, 2016*

**Advantar Laboratories (San Diego, California, USA)** a GLP/GMP analytical testing CRO, was acquired by Eurofins. *Source: BioPharma-Reporter.com, April 1, 2016*

**Repligen** acquired Atoll AG (Weingarten, Germany), like itself, another major supplier of pre-filled chromatography columns.

*Source: GEN News Highlights, April 4, 2016*

**Aptuit, LLC**, acquired Exquiron Biotech AG (Basel, Switzerland), “a fully integrated outsourced discovery services” CRO. *Source:*

*Pharmaceutical Outsourcing, April 21, 2016*

**Quintiles**, the largest CRO, merged with IMS Health. The new co. will have about 50,000 staff worldwide. *Source: FierceBiotech, May 6, 2016*

**Samsung Biologics (Songdo, S. Korea)**, a biopharma CMO with the largest capacity of all bioprocessing facilities, will issue an IPO and go public later this year. *Source: BioPharma-Reporter.com, April 29, 2016*